Emerging monoclonal antibodies against Clostridium difficile infection

Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection

(2017) Mark H. Wilcox et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clostridium difficile flagella predominantly activate TLR5-linked NF-κB pathway in epithelial cells

(2016) Jameel Batah et al.   ANAEROBE

Immunogenic properties of the surface layer precursor of Clostridium difficile and vaccination assays in animal models

(2016) J.-F. Bruxelle et al.   ANAEROBE

Virulence factors of Clostridium difficile and their role during infection

(2016) Claire Janoir   ANAEROBE

Disease Progression and Resolution in Rodent Models of Clostridium difficile Infection and Impact of Antitoxin Antibodies and Vancomycin

(2016) Peter Warn et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A Tetraspecific VHH-Based Neutralizing Antibody Modifies Disease Outcome in Three Animal Models of Clostridium difficile Infection

(2016) Diane J. Schmidt et al.   Clinical and Vaccine Immunology

Antibodies to Toxin B Are Protective AgainstClostridium difficileInfection Recurrence

(2016) Swati B. Gupta et al.   CLINICAL INFECTIOUS DISEASES

Intravenous adenovirus expressing a multi-specific, single-domain antibody neutralizing TcdA and TcdB protects mice fromClostridium difficileinfection

(2016) Zhiyong Yang et al.   Pathogens and Disease

Immunogenicity and protective efficacy of recombinant Clostridium difficile flagellar protein FliC

(2016) Chandrabali Ghose et al.   Emerging Microbes & Infections

The binary toxin CDT enhances Clostridium difficile virulence by suppressing protective colonic eosinophilia

(2016) Carrie A. Cowardin et al.   Nature Microbiology

Characteristics of theClostridium difficilecell envelope and its importance in therapeutics

(2016) Joseph A. Kirk et al.   Microbial Biotechnology

Recurrent Clostridium difficile infection: From colonization to cure

(2015) Kelsey Shields et al.   ANAEROBE

Targeting surface-layer proteins with single-domain antibodies: a potential therapeutic approach against Clostridium difficile-associated disease

(2015) Hiba Kandalaft et al.   APPLIED MICROBIOLOGY AND BIOTECHNOLOGY

A Combination of Three Fully Human Toxin A- and Toxin B-Specific Monoclonal Antibodies Protects against Challenge with Highly Virulent Epidemic Strains of Clostridium difficile in the Hamster Model

(2015) Natalie G. Anosova et al.   Clinical and Vaccine Immunology

Neutralization of Clostridium difficile Toxin B Mediated by Engineered Lactobacilli That Produce Single-Domain Antibodies

(2015) Kasper Krogh Andersen et al.   INFECTION AND IMMUNITY

Hospital cost of Clostridium difficile infection including the contribution of recurrences in French acute-care hospitals

(2015) A. Le Monnier et al.   JOURNAL OF HOSPITAL INFECTION

Burden of Clostridium difficile Infection in the United States

(2015) Fernanda C. Lessa et al.   NEW ENGLAND JOURNAL OF MEDICINE

Selection of Nanobodies that Block the Enzymatic and Cytotoxic Activities of the Binary Clostridium Difficile Toxin CDT

(2015) Mandy Unger et al.   Scientific Reports

Passive and active immunization strategies against Clostridium difficile infections: State of the art

(2014) Assaf Mizrahi et al.   ANAEROBE

The role of the humoral immune response to Clostridium difficile toxins A and B in susceptibility to C. difficile infection: A case–control study

(2014) J. Islam et al.   ANAEROBE

Broad Coverage of Genetically Diverse Strains of Clostridium difficile by Actoxumab and Bezlotoxumab Predicted byIn VitroNeutralization and Epitope Modeling

(2014) Lorraine D. Hernandez et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Mutational approaches to improve the biophysical properties of human single-domain antibodies

(2014) Dae Young Kim et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

Mechanisms of Protection against Clostridium difficile Infection by the Monoclonal Antitoxin Antibodies Actoxumab and Bezlotoxumab

(2014) Zhiyong Yang et al.   INFECTION AND IMMUNITY

Toxin-Mediated Paracellular Transport of Antitoxin Antibodies Facilitates Protection against Clostridium difficile Infection

(2014) Z. Zhang et al.   INFECTION AND IMMUNITY

Mechanism of Action and Epitopes ofClostridium difficileToxin B-neutralizing Antibody Bezlotoxumab Revealed by X-ray Crystallography

(2014) Peter Orth et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A Novel Multivalent, Single-Domain Antibody Targeting TcdA and TcdB Prevents Fulminant Clostridium difficile Infection in Mice

(2014) Zhiyong Yang et al.   JOURNAL OF INFECTIOUS DISEASES

A Novel Secreted Metalloprotease (CD2830) fromClostridium difficileCleaves Specific Proline Sequences in LPXTG Cell Surface Proteins

(2014) Paul J. Hensbergen et al.   MOLECULAR & CELLULAR PROTEOMICS

A Mixture of Functionally Oligoclonal Humanized Monoclonal Antibodies That Neutralize Clostridium difficile TcdA and TcdB with High Levels ofIn VitroPotency ShowsIn VivoProtection in a Hamster Infection Model

(2013) Nicola L. Davies et al.   Clinical and Vaccine Immunology

Protective Efficacy Induced by Recombinant Clostridium difficile Toxin Fragments

(2013) Rosanna Leuzzi et al.   INFECTION AND IMMUNITY

Structural Basis for Antibody Recognition in the Receptor-binding Domains of Toxins A and B fromClostridium difficile

(2013) Tomohiko Murase et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Importance of Toxin A, Toxin B, and CDT in Virulence of an Epidemic Clostridium difficile Strain

(2013) Sarah A. Kuehne et al.   JOURNAL OF INFECTIOUS DISEASES

The Role of Flagella in Clostridium difficile Pathogenesis: Comparison between a Non-Epidemic and an Epidemic Strain

(2013) Soza T. Baban et al.   PLoS One

Identification of a Novel Zinc Metalloprotease through a Global Analysis of Clostridium difficile Extracellular Proteins

(2013) Valeria Cafardi et al.   PLoS One

Potent monoclonal antibodies againstClostridium difficiletoxin A elicited by DNA immunization

(2013) Chunhua Zhang et al.   Human Vaccines & Immunotherapeutics

A Chimeric Toxin Vaccine Protects against Primary and Recurrent Clostridium difficile Infection

(2012) Haiying Wang et al.   INFECTION AND IMMUNITY

Protection Against Clostridium difficile Infection With Broadly Neutralizing Antitoxin Monoclonal Antibodies

(2012) Andre J. Marozsan et al.   JOURNAL OF INFECTIOUS DISEASES

A Novel Strategy for Development of Recombinant Antitoxin Therapeutics Tested in a Mouse Botulism Model

(2012) Jean Mukherjee et al.   PLoS One

Encapsulation of Cwp84 into pectin beads for oral vaccination against Clostridium difficile

(2011) Chiara Sandolo et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Immunization of hamsters againstClostridium difficileinfection using the Cwp84 protease as an antigen

(2011) Séverine Péchiné et al.   FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY

Development and Evaluation of an Ovine Antibody-Based Platform for Treatment of Clostridium difficile Infection

(2011) April Roberts et al.   INFECTION AND IMMUNITY

Neutralization ofClostridium difficileToxin A with Single-domain Antibodies Targeting the Cell Receptor Binding Domain

(2011) Greg Hussack et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Therapeutic potential of egg yolk antibodies for treating Clostridium difficile infection

(2011) G. L. Mulvey et al.   JOURNAL OF MEDICAL MICROBIOLOGY

Engineered Single-Domain Antibodies with High Protease Resistance and Thermal Stability

(2011) Greg Hussack et al.   PLoS One

Lipolysis-stimulated lipoprotein receptor (LSR) is the host receptor for the binary toxin Clostridium difficile transferase (CDT)

(2011) P. Papatheodorou et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The role of toxin A and toxin B in Clostridium difficile infection

(2010) Sarah A. Kuehne et al.   NATURE

Treatment with Monoclonal Antibodies againstClostridium difficileToxins

(2010) Israel Lowy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Enhancement of toxin- and virus-neutralizing capacity of single-domain antibody fragments by N-glycosylation

(2009) M. M. Harmsen et al.   APPLIED MICROBIOLOGY AND BIOTECHNOLOGY

New trends in Clostridium difficile virulence and pathogenesis

(2009) C. Denève et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Toxin B is essential for virulence of Clostridium difficile

(2009) Dena Lyras et al.   NATURE

Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI)

(2009) Brett A. Leav et al.   VACCINE

Immunoreactive cell wall proteins of Clostridium difficile identified by human sera

(2008) A. Wright et al.   JOURNAL OF MEDICAL MICROBIOLOGY

Structure and mode of action of clostridial glucosylating toxins: the ABCD model

(2008) Thomas Jank et al.   TRENDS IN MICROBIOLOGY

Open-label, dose escalation phase I study in healthy volunteers to evaluate the safety and pharmacokinetics of a human monoclonal antibody to Clostridium difficile toxin A

(2008) Claribel P. Taylor et al.   VACCINE